Scientists welcome ruling on patent on breast cancer geneBMJ 2007; 335 doi: https://doi.org/10.1136/bmj.39360.646435.DB (Published 11 October 2007) Cite this as: BMJ 2007;335:740
- Rory Watson
The European Patent Office has rejected an appeal by the US drug company Myriad Genetics and the University of Utah against an earlier decision revoking the patent concerning the BRCA1 gene and its applications.
The ruling has been welcomed by European researchers working on tests for a predisposition to breast and ovarian cancer. Dominique Stoppa-Lyonnet, head of the genetics department at the Institut Curie in Paris, said: “This is an important decision, since it means we can continue our work without fear of being attacked for infringing a patent.”
The decision is the latest stage in …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial